We just got more 'hopeful' data on Gilead's potential coronavirus treatment, but it's too soon to tell if the drug works

Associated Press More than two-thirds of hospitalized COVID-19 patients improved in condition after receiving remdesivir, an experimental antiviral treatment from Gilead Sciences. These findings come from data published Friday on 53 patients, the largest dataset yet for remdesivir. Experts, including the lead author of this study, cautioned against reaching conclusions on the drug's efficacy. This is because the trial had no control arm to compare the results with. High-quality data is coming so...